Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses immunotherapy in bladder cancer.
Jean Hoffman-Censits, MD, associate professor of medical oncology, Thomas Jefferson University Hospital, Sidney Kimmel Cancer Center, discusses immunotherapy in bladder cancer.
For patients with metastatic urothelial carcinoma who are platinum refractory, and for those patients who are not candidates for cisplatin, immunotherapy is the current standard of care.
Dr Tolaney on Final OS Data From the TROPiCS-02 Trial in HR+/HER2- Breast Cancer
BL-B01D1 Demonstrates Antitumor Activity in EGFR+ NSCLC and Other Solid Tumors
Sotorasib Provides Consistent Clinical Benefit Over Docetaxel in Key Co-Alteration Subgroups of KRAS G12C+ NSCLC
Dabrafenib and Trametinib Plus Navitoclax Meets CR End Point in BRAF V600–mutant Metastatic Melanoma